AAM
AZN icon

American Asset Management’s AstraZeneca AZN Stock Holding History

American Asset Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-9
Closed -$1K – 14
2015
Q3 		$1K Buy
+9
New +$592 ﹤0.01% 100

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
EIP
Epoch Investment Partners New York $16.5B AUM 24.3% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.16B AUM 16.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
SCCM
Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

American Asset Management's AZN Position: Q4 2015 in Review

American Asset Management sold out of AstraZeneca (AZN) in Q4 2015, closing a stake of 9 shares — an estimated $1K sold.

American Asset Management first reported a position in AZN in Q3 2015 and held it in 1 quarter. The position peaked at $1K in Q3 2015. 389 funds tracked by Wall St. Rank hold AZN as of Q4 2015.

  • American Asset Management reported no remaining AstraZeneca position as of Q4 2015 after selling out during the quarter.
  • American Asset Management sold 9 AstraZeneca shares in Q4 2015, an estimated $1K.
  • American Asset Management first reported a position in AstraZeneca in Q3 2015 and held it in 1 quarter.
  • American Asset Management's AstraZeneca position peaked at $1K in Q3 2015.
  • 389 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2015.

Based on American Asset Management's 13F filing for Q4 2015, filed 19 Jan 2016.